Citadel Advisors
ETON icon

Citadel Advisors’s Eton Pharmaceutcials ETON Stock Holding History

Citadel Advisors’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
36,400
+6,400
+21% +$188K ﹤0.01% 7521
2026
Q1 		$740K Buy
+30,000
New +$525K ﹤0.01% 8388
2025
Q2 		– Sell
-13,400
Closed -$174K – 13218
2025
Q1 		$174K Buy
13,400
+9,200
+219% +$139K ﹤0.01% 10647
2024
Q4 		$55.9K Buy
4,200
+3,700
+740% +$37.5K ﹤0.01% 12270
2024
Q3 		$3K Sell
500
-500
-50% -$2.11K ﹤0.01% 13700
2024
Q2 		$3.29K Buy
+1,000
New +$3.5K ﹤0.01% 13609
2024
Q1 		– Sell
-3,100
Closed -$13.6K – 14770
2023
Q4 		$13.6K Buy
3,100
+1,100
+55% +$4.41K ﹤0.01% 12923
2023
Q3 		$8.34K Buy
2,000
+900
+82% +$3.47K ﹤0.01% 13196
2023
Q2 		$3.84K Buy
1,100
+1,000
+1,000% +$3.68K ﹤0.01% 13654
2023
Q1 		$385 Buy
+100
New +$365 ﹤0.01% 14506
2022
Q1 		– Sell
-15,600
Closed -$67K – 13844
2021
Q4 		$67K Sell
15,600
-6,000
-28% -$28.7K ﹤0.01% 13065
2021
Q3 		$109K Sell
21,600
-7,100
-25% -$36.9K ﹤0.01% 12768
2021
Q2 		$177K Buy
+28,700
New +$213K ﹤0.01% 12306

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

Citadel Advisors's ETON Position: Q2 2026 in Review

Citadel Advisors reduced its Eton Pharmaceutcials (ETON) stake by 55% in Q2 2026, selling an estimated $1.73M and leaving 48,969 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #6839.

Citadel Advisors first reported a position in ETON in Q3 2020 and has held it in 15 quarters since. The position peaked at $2.66M in Q1 2026. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Citadel Advisors held 48,969 shares of Eton Pharmaceutcials worth $1.77M as of Q2 2026.
  • Citadel Advisors sold 58,846 Eton Pharmaceutcials shares in Q2 2026, an estimated $1.73M.
  • Eton Pharmaceutcials made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6839 holding.
  • Citadel Advisors first reported a position in Eton Pharmaceutcials in Q3 2020 and has held it in 15 quarters since.
  • Citadel Advisors's Eton Pharmaceutcials position peaked at $2.66M in Q1 2026.
  • 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.